ENVERIC BIOSCIENCES INC (ENVB)

ENVB Stock Earnings: Enveric Biosciences Beats EPS for Q4 2023

ENVB stock results show that Enveric Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today?

Investors in Enveric Biosciences are seeing massive gains today, as ENVB stock more than doubles on a huge uptick in trading volume.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning!

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)

The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.